Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
domingo, octubre 04
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Halozyme Therapeutics Inc
HALO
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$109.86
2.92
2.73%
Últ. Act.: Oct 2, 4:00 PM
$109.86
2.92
2.73%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Halozyme Therapeutics Financials
Halozyme Therapeutics (HALO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Halozyme Therapeutics Q2 Adj. EPS $2.28 Beats $1.84 Estimate, Sales $480.999M Beat $407.493M Estimate
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $2.28 per share which beat the analyst consensus estimate of $1.84 by 23.91 percent. This is a 48.05 percent increase over earnings of $1.54 per share
Benzinga Newsdesk
PRO
Halozyme Therapeutics Raises FY2026 Adj EPS Guidance from $7.75-$8.25 to $8.65-$9.00 vs $8.14 Est; Raises FY2026 Sales Guidance from $1.710B-$1.810B to $1.835B-$1.910B vs $1.773B Est
Halozyme Therapeutics (NASDAQ:HALO) raises FY2026 Adj EPS guidance from $7.75-$8.25 to $8.65-$9.00 vs $8.14 analyst estimate. Raises FY2026 sales outlook from $1.710 billion-$1.810 billion to $1.835 billion-$1.910
Benzinga Newsdesk
PRO
Halozyme Therapeutics Affirms FY2026 Adj EPS Guidance of $7.75-$8.25 vs $8.09 Est; Affirms FY2026 Sales Guidance of $1.710B-$1.810B vs $1.760B Est
Halozyme Therapeutics (NASDAQ:HALO) affirms FY2026 Adj EPS guidance from $7.75-$8.25 to $7.75-$8.25 vs $8.09 analyst estimate. Affirms FY2026 sales outlook from $1.710 billion-$1.810 billion to $1.710 billion-$1.810
Benzinga Newsdesk
PRO
Halozyme Therapeutics Q1 Adj. EPS $1.60 Beats $1.53 Estimate, Sales $376.708M Beat $359.053M Estimate
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $1.60 per share which beat the analyst consensus estimate of $1.53 by 4.58 percent. This is a 44.14 percent increase over earnings of $1.11 per share
Benzinga Newsdesk
Earnings Scheduled For May 11, 2026
Benzinga Insights
Halozyme Therapeutics Earnings Report: Q4 Overview
Benzinga Insights
